Takeda to Divest a Portfolio of Select OTC and Non-Core Assets to Hypera Pharma in Latin America for $825M

 Takeda to Divest a Portfolio of Select OTC and Non-Core Assets to Hypera Pharma in Latin America for $825M

Takeda to Divest a Portfolio of Select OTC and Non-Core Assets to Hypera Pharma in Latin America for $825M

Shots:

  • Takeda will divest a portfolio of ~18 select OTC and prescription pharmaceutical assets including Neosaldina, Nesina, and Dramin sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru to Hypera for a total value ~$825M. The transaction is expected to be close in H2’20
  • Takeda expects that its ~300 employees supporting the divested assets will be given the opportunity to transition over to Hypera. Additionally, Takeda and Hypera Pharma signed a manufacturing & supply agreement under which Takeda will manufacture the products and supply them to Hypera
  • The divestiture marks Takeda’s fifth divestment over the last 12mos. and allow the company to focus on its key areas by simplifying its portfolio

Click here ­to­ read full press release/ article | Ref: Takeda | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post